BIORA THERAPEUTICS, INC.
BIOR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BIOR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2024.
Tracking 4 pipeline candidates for BIORA THERAPEUTICS, INC..
Run BIORA THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BIORA THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
1.4 months
OCF -$9M · Net income -$18M
Lead: Phase 1
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Frequently asked questions
What is BIORA THERAPEUTICS, INC.'s lead drug candidate?
BIORA THERAPEUTICS, INC.'s most advanced tracked candidate is bt-001 (Preclinical) for ulcerative colitis.
Who is the CEO of BIORA THERAPEUTICS, INC.?
Adi Mohanty is the chief executive officer of BIORA THERAPEUTICS, INC. (BIOR).
What therapeutic areas does BIORA THERAPEUTICS, INC. focus on?
BIORA THERAPEUTICS, INC. develops therapies across Immunology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.